<DOC>
	<DOCNO>NCT02187783</DOCNO>
	<brief_summary>The purpose signal seek study determine whether treatment LEE011 demonstrate sufficient efficacy CDK4/6 pathway activate solid tumor and/or hematologic malignancy warrant study .</brief_summary>
	<brief_title>LEE011 Patients With CDK4/6 Pathway Activated Tumors ( SIGNATURE )</brief_title>
	<detailed_description />
	<criteria>Patient confirm diagnosis select solid tumor ( except breast cancer ( however , triple negative include ) , liposarcoma , CRPC , melanoma teratoma ) hematological malignancy ( except mantle cell lymphoma ) . Patient must preidentified tumor CDK4 amplification mutation , CDK6 amplification mutation , Cyclin D1 ( CCND1 ) amplification , Cyclin D3 ( CCND3 ) amplification , p16 ( CDKN2A ) mutation Patient receive least one prior treatment recurrent , metastatic /or locally advance disease standard therapy option anticipate result durable remission . Patient progressive measurable disease per RECIST 1.1. appropriate hematological guideline . Patient Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 1 Patients receive prior treatment LEE011 . Patient clinically significant rest bradycardia ( heart rate &lt; 50 rest ) , tachycardia ( heart rate &gt; 90 rest ) , PR interval &gt; 220 msec , QRS interval &gt; 109 msec , QTcF &gt; 450 msec . Patients primary CNS tumor CNS tumor involvement Patient receive chemotherapy anticancer therapy ≤ 4 week prior start study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Solid malignancy ,</keyword>
	<keyword>Hematologic malignancy ,</keyword>
	<keyword>Mutations ,</keyword>
	<keyword>Amplifications ,</keyword>
	<keyword>Signature ,</keyword>
	<keyword>CDK4 ,</keyword>
	<keyword>CDK6 ,</keyword>
	<keyword>CDK4/6 ,</keyword>
	<keyword>Cyclin D1 ,</keyword>
	<keyword>CCND1 ,</keyword>
	<keyword>Cyclin D3 ,</keyword>
	<keyword>CCND3 ,</keyword>
	<keyword>p16 mutation ,</keyword>
	<keyword>CDKN2A ,</keyword>
	<keyword>LEE011 ,</keyword>
	<keyword>Breast cancer ,</keyword>
	<keyword>Ovarian cancer ,</keyword>
	<keyword>Lymphoma ,</keyword>
	<keyword>Mesothelioma ,</keyword>
	<keyword>Pancreatic neuroendocrine ,</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Tumor</keyword>
</DOC>